LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

By LabMedica International staff writers
Posted on 05 Nov 2024
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI models requires large datasets, which are typically abundant for common diseases. The real challenge lies in accurately detecting rarer diseases, which many current AI models tend to overlook or misclassify. Researchers have now created a new AI tool designed to utilize imaging data to identify less common gastrointestinal tract diseases effectively.

Developed by scientists at Ludwig Maximilian University of Munich (Munich, Germany) and their collaborators, this innovative model only requires training data from frequently observed conditions to reliably detect rarer diseases. This advancement has the potential to enhance diagnostic accuracy and alleviate the workloads of pathologists in the future. As reported in the New England Journal of Medicine AI (NEJM AI), the new technique is founded on anomaly detection. The model learns to identify and highlight deviations from the precise characterization of normal tissues and findings from common diseases, without the need for specific training on these less frequent cases. The researchers utilized a dataset of 17 million histological images from 5,423 cases for training and evaluation.

In their research, the team gathered two extensive datasets of microscopic images from gastrointestinal biopsy tissue sections, along with their corresponding diagnoses. In these datasets, the ten most common findings—including normal observations and prevalent diseases such as chronic gastritis—constituted approximately 90% of cases, while the remaining 10% encompassed 56 different disease entities, including various cancers. Additionally, the AI model employs heatmaps to visually indicate the location of anomalies within the tissue section. By distinguishing normal findings and common diseases while detecting anomalies, the AI model is poised to offer crucial support to healthcare professionals. Although the identified diseases still require validation by pathologists, this AI tool can significantly reduce diagnostic time, as it enables automatic diagnosis of normal findings and a portion of diseases.

“We compared various technical approaches and our best model detected with a high degree of reliability a broad range of rarer pathologies of the stomach and colon, including rare primary or metastasizing cancers. To our knowledge, no other published AI tool is capable of doing this,” said Professor Frederick Klauschen, Director of the Institute of Pathology at LMU.

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more